Media, Morphokinetics, and Mosaicism (3M)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03503877 |
|
Recruitment Status :
Completed
First Posted : April 20, 2018
Last Update Posted : June 10, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Embryonic Mosaicism Embryo Culture Media Embryo Morphokinetics Infertility | Device: EmbryoScope Plus Other: GLOBAL MEDIA Other: SAGE MEDIA | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 128 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | sibling embryo study |
| Masking: | Triple (Participant, Care Provider, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Aneuploidy Rates and Morphokinetic Parameters in Sibling Embryos Cultured in Distinct Culture Media |
| Actual Study Start Date : | February 14, 2018 |
| Actual Primary Completion Date : | November 28, 2019 |
| Actual Study Completion Date : | November 28, 2019 |
| Arm | Intervention/treatment |
|---|---|
|
SAGE Media
SAGE single-step MEDIA
|
Device: EmbryoScope Plus
All embryos will be cultured in the EmbryoScope Plus to obtain morphokinetic data Other: SAGE MEDIA Embryos will be cultured in SAGE media |
|
GLOBAL Media
LIFE GLOBAL single-step MEDIA
|
Device: EmbryoScope Plus
All embryos will be cultured in the EmbryoScope Plus to obtain morphokinetic data Other: GLOBAL MEDIA Embryos will be cultured in GLOBAL media |
- aneuploidy rates [ Time Frame: 2 weeks ]number of embryos with abnormal chromosome number over total number of embryos biopsied
- embryo quality [ Time Frame: 2 weeks ]fraction of freezable quality embryos (6c or greater, grades 1-2 for symmetry and fragmentation)
- embryonic mosaicism [ Time Frame: 2 weeks ]fraction of embryos defined as mosiac (number of embryos with partial aneuploidy over total number of embryos biopsied)
- embryo morphokinetics [ Time Frame: 2 weeks ]time of first and subsequent cleavage, time between cleavages
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 42 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
All subjects planning blastocyst culture for preimplantation genetic screening (PGS) will be offered enrollment.
Antral Follicle Count (AFC) >8 Male and female partner > 18 years of age
Exclusion Criteria:
Female partner age >42 years of age Cleavage stage biopsy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03503877
| United States, California | |
| University of California San Francisco | |
| San Francisco, California, United States, 94158 | |
| Principal Investigator: | Mitchell Rosen, MD | University of California, San Francisco |
| Responsible Party: | University of California, San Francisco |
| ClinicalTrials.gov Identifier: | NCT03503877 |
| Other Study ID Numbers: |
17-22331 |
| First Posted: | April 20, 2018 Key Record Dates |
| Last Update Posted: | June 10, 2021 |
| Last Verified: | June 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
| Device Product Not Approved or Cleared by U.S. FDA: | Yes |
|
Infertility |

